Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002, China.
Laboratory of Urology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.
Virus Res. 2014 Mar 6;181:61-71. doi: 10.1016/j.virusres.2013.12.021. Epub 2014 Jan 21.
RNA interference has been proven to be a powerful tool for gene knockdown. Our previous study demonstrated that a Ki67 shRNA carried by an adenovirus reduced Ki67 expression. In this study, we constructed novel oncolytic adenoviruses in which the Ki67 core promoter drove expression of the E1A gene. These adenoviruses were equipped with either a Ki67 small interfering RNA (siRNA), a human telomerase reverse transcriptase (hTERT) siRNA or a double siRNA targeting Ki67 and hTERT. We identified the antitumor activities of oncolytic adenoviruses in 3 renal cancer cell lines, human normal renal tube cell HK-2 and also in nude mice bearing KETR-3-xenografted tumors. Our results showed that these oncolytic adenoviruses, especially Ki67-ZXC2-double siRNA, could effectively induce silencing of the Ki67 and hTERT genes, allow efficient viral replication and induce significant apoptosis of renal cancer cells in vitro and in nude mice. We concluded that a dual siRNA mediated by oncolytic virotherapy could be an effective strategy for cancer gene therapy.
RNA 干扰已被证明是基因敲低的有力工具。我们之前的研究表明,腺病毒携带的 Ki67 shRNA 可降低 Ki67 的表达。在这项研究中,我们构建了新型溶瘤腺病毒,其中 Ki67 核心启动子驱动 E1A 基因的表达。这些腺病毒携带 Ki67 小干扰 RNA(siRNA)、人端粒酶逆转录酶(hTERT)siRNA 或靶向 Ki67 和 hTERT 的双 siRNA。我们鉴定了溶瘤腺病毒在 3 种肾癌细胞系、人正常肾小管细胞 HK-2 以及携带 KETR-3-异种移植瘤的裸鼠中的抗肿瘤活性。我们的结果表明,这些溶瘤腺病毒,尤其是 Ki67-ZXC2-双 siRNA,可有效诱导 Ki67 和 hTERT 基因沉默,允许病毒有效复制,并在体外和裸鼠中诱导肾癌细胞显著凋亡。我们得出结论,溶瘤病毒治疗介导的双 siRNA 可能是癌症基因治疗的有效策略。